AAV2-GDNF ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
6パーキンソン病2

6. パーキンソン病


臨床試験数 : 2,307 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04167540
(ClinicalTrials.gov)
April 1, 20207/11/2019GDNF Gene Therapy for Parkinson's DiseaseOpen-Label Safety Study of Glial Cell Line-Derived Neurotrophic Factor Gene Transfer (AAV2- GDNF) in Parkinson's DiseaseParkinson's DiseaseBiological: AAV2-GDNFBrain Neurotherapy Bio, Inc.Asklepios Biopharmaceutical, Inc.;California Institute for Regenerative Medicine (CIRM)Active, not recruiting35 Years75 YearsAll11Phase 1United States
2NCT01621581
(ClinicalTrials.gov)
March 13, 201314/6/2012AAV2-GDNF for Advanced Parkinson s DiseaseA Phase 1 Open-Label Dose Escalation Safety Study of Convection Enhanced Delivery (CED) of Adeno-Associated Virus Encoding Glial Cell Line-Derived Neurotrophic Factor (AAV2-GDNF) in Subjects With Advanced Parkinson's Disease.Parkinson's DiseaseGenetic: Convection enhanced delivery/AAV2-GDNFNational Institute of Neurological Disorders and Stroke (NINDS)NULLCompleted18 YearsN/AAll25Phase 1United States